Brief: Citius Oncology Announces U.S. Commercial Launch Of Lymphir For Cutaneous T-Cell Lymphoma
01/12/2025 18:31
Dec 1 (Reuters) - Citius Oncology Inc CTOR.O: CITIUS ONCOLOGY ANNOUNCES U.S. COMMERCIAL LAUNCH OF LYMPHIR™, A NOVEL CANCER IMMUNOTHERAPY FOR CUTANEOUS T-CELL LYMPHOMA (CTCL) CITIUS ONCOLOGY ANNOUNCES U.S. COMMERCIAL LAUNCH OF LYMPHIR™, A NOVEL CANCER IMMUNOTHERAPY FOR CUTANEOUS T-CELL LYMPHOMA (CTCL) Source text: ID:nPn3zMLYca Further company coverage: CTOR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Citius Oncology
See all newsCitius Oncology Inc reports results for the quarter ended June 30 - Earnings Summary
Citius Oncology Inc expected to post a loss of 5 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-AnaptysBio, Tesla, Intel
U.S. STOCKS ON THE MOVE-Dycom Industries, Robinhood, Brown-Forman
Citius rises as lymphoma drug shows benefit in patients before CAR-T therapy